Area of leased property (sqft) Area of Real Estate Property Commercial and corporate obligations Commercial And Corporate Obligations [Member] Commercial And Corporate Obligations [Member] Document Type Document Type Aggregate intrinsic value, options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Other income, net Other Nonoperating Income (Expense) Issued and Outstanding: Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract] Anti-PD-1 (JEMPERLI/Dostarlimab) Anti-PD-1 AnaptysBio-generated Anti-PD-1 (JEMPERLI/Dostarlimab) [Member] AnaptysBio-generated Anti-PD-1 (JEMPERLI/Dostarlimab) Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Annual increase in number of shares available for issuance Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding Available-for-sale securities, debt securities Total Fair Value Debt Securities, Available-for-sale Equity Components [Axis] Equity Components [Axis] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Minimum Minimum [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Operating lease liabilities, Other current liabilities Operating Lease, Liability, Current Payments on notes payable Repayments of Notes Payable Accrued research, development and manufacturing expenses Accrued Research And Development Expenses, Current Accrued Research And Development Expenses, Current Statistical Measurement [Domain] Statistical Measurement [Domain] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Summary of Weighted Average Assumptions in Stock Option Valuations Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Entity Interactive Data Current Entity Interactive Data Current Exercises (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Security Exchange Name Security Exchange Name Fair Value Measurements and Available for Sale Investments Fair Value Disclosures [Text Block] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Summary of Activity Related to Stock Option Awards Share-based Payment Arrangement, Option, Activity [Table Text Block] Phase 3 clinical trial initiation - first indication Phase 3 Clinical Trial Initiation - First Indication [Member] Phase 3 Clinical Trial Initiation - First Indication Loss from operations Operating Income (Loss) Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Total current liabilities Liabilities, Current FDA approval Food and Drug Administration Approval [Member] Food and Drug Administration Approval Entity Registrant Name Entity Registrant Name Subsequent Event Type [Domain] Subsequent Event Type [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Accrued professional fees Accrued Professional Fees, Current Long-term investments Debt Securities, Available-for-sale, Noncurrent ASSETS Assets [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Award vesting period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Filing of the first BLA - second indication Filing of BLA - Second Indication [Member] Filing of BLA - Second Indication Accounting Policies [Abstract] Accounting Policies [Abstract] Weighted-Average Exercise Price per Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Number of reportable segments Number of Reportable Segments Entity Address, State or Province Entity Address, State or Province Cash paid for amounts included in the measurement of lease liabilities Operating Lease, Payments Accounts payable Accounts Payable, Current Research and development Research and Development Expense [Member] Schedule of Common Stock Reserved for Future Issuance Schedule Of Common Stock Reserved For Future Issuance [Table Text Block] Schedule Of Common Stock Reserved For Future Issuance [Table Text Block] Accumulated deficit Retained Earnings (Accumulated Deficit) Operating ROU assets, Other long-term assets Operating Lease, Right-of-Use Asset Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Total minimum payments required Lessee, Operating Lease, Liability, to be Paid TESARO GlaxoSmithKline [Member] GlaxoSmithKline Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] Royalty percent on net sales Net Sales Royalty, Percent Net Sales Royalty, Percent 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Entity Addresses [Line Items] Entity Addresses [Line Items] Stock options issued and outstanding (in shares) Stock options outstanding, beginning balance (in shares) Stock options outstanding, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Schedule of Assets and Liabilities that Require Fair Value Measurements on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] IND clearance from the FDA Clearance Of Investigational New Drug From FDA [Member] Clearance Of Investigational New Drug From FDA [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Monthly base rate (usd per sqft) Rent Per Square Foot Rent Per Square Foot Schedule of ROU Assets and Lease Liabilities Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Stockholders' Equity, Beginning Balance (in shares) Stockholders' Equity, Ending Balance (in shares) Shares, Outstanding Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at March 31, 2021 and December 31, 2020, respectively Preferred Stock, Value, Issued Unrealized losses on available-for-sale Debt Securities, Available-for-sale, Unrealized Loss Investments outstanding, maturity date range (in years) Available-for-sale Debt Securities, Remaining Maturity Available-for-sale Debt Securities, Remaining Maturity Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Total operating expenses Operating Expenses Document Transition Report Document Transition Report Stock options exercisable, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Maximum milestone payments per target Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Title of Individual [Axis] Title of Individual [Axis] 12 Months or Greater, Gross Unrealized Losses Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Forfeitures and cancellations (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Other income, net: Nonoperating Income (Expense) [Abstract] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Document Quarterly Report Document Quarterly Report Forfeitures and cancellations (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax Measurement Frequency [Domain] Measurement Frequency [Domain] General and administrative General and Administrative Expense [Member] Equity [Abstract] Equity [Abstract] Milestone payments, contingent upon achievement of specified levels of worldwide sales (up to) Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Investments at fair value Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure Non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Award expiration period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Statement [Line Items] Statement [Line Items] Mutual funds Mutual Fund [Member] Schedule of Outstanding Potentially Dilutive Securities Excluded in the Calculation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Net loss per common share: Earnings Per Share, Basic and Diluted [Abstract] Accretion/amortization of investments, net Unrealized Gain (Loss) on Investments Expected term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Entity File Number Entity File Number Statement [Table] Statement [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Phase 3 clinical trial initiation - second indication Phase 3 clinical Trial Initiation - Second Indication [Member] Phase 3 clinical Trial Initiation - Second Indication [Member] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Four Lessee, Operating Lease, Liability, to be Paid, after Year Four Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Agency securities US Government Agencies Debt Securities [Member] Lease termination term Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period Celgene Corporation Bristol-Myers Squibb [Member] Bristol-Myers Squibb Counterparty Name [Axis] Counterparty Name [Axis] Weighted-average number of shares outstanding: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Common stock, $0.001 par value, 500,000 shares authorized, 27,367 shares and 27,356 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively Common Stock, Value, Issued Basic and diluted (in dollars per share) Earnings Per Share, Basic and Diluted Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Document Fiscal Year Focus Document Fiscal Year Focus Entity Small Business Entity Small Business Basis of Consolidation Consolidation, Policy [Policy Text Block] Revenue Recognition [Abstract] Revenue Recognition [Abstract] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Restricted cash Restricted Cash, Current Aggregate intrinsic value, options exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Entity Current Reporting Status Entity Current Reporting Status Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Milestone payments, contingent upon preclinical and clinical trial events (up to) Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events Weighted average remaining contractual term, options exercisable (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Collaborative Research And Development Agreement Collaborative Arrangement [Member] Sales and maturities of investments Proceeds from Sale and Maturity of Debt Securities, Available-for-sale Amendment Flag Amendment Flag Subsequent Event [Table] Subsequent Event [Table] Acquisition of investments Payments to Acquire Debt Securities, Available-for-sale Net Loss Per Common Share Earnings Per Share, Policy [Policy Text Block] Prepaid rent Prepaid Rent Increase in annual rent Annual Rent Increase, Percent Annual Rent Increase, Percent Receivable from collaborative partners Increase (Decrease) in Contract with Customer, Asset Stock-based compensation Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Former Address Former Address [Member] Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Collaborative Research and Development Agreements Collaborative Arrangement Disclosure [Text Block] CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Shares reserved for future award grants (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Other Other Accrued Liabilities, Current Balance Sheet Accounts and Supplemental Disclosures Supplemental Balance Sheet Disclosures [Text Block] 2017 Equity Incentive Plan 2017 Plan Equity Incentive Plan, 2017 [Member] Equity Incentive Plan, 2017 [Member] Total Operating Lease, Liability Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Entity Central Index Key Entity Central Index Key Measurement Frequency [Axis] Measurement Frequency [Axis] Short-term investments Debt Securities, Available-for-sale, Current Capital shares reserved for future issuance, increase (in shares) Common Stock, Capital Shares Reserved For Future Issuance, Increase Common Stock, Capital Shares Reserved For Future Issuance, Increase Financial Instruments [Domain] Financial Instruments [Domain] Total stockholders’ equity Stockholders' Equity, Beginning Balance Stockholders' Equity, Ending Balance Stockholders' Equity Attributable to Parent Amendment Collaboration and Exclusive License Agreement [Member] Collaboration and Exclusive License Agreement Description of the Business Nature of Operations [Text Block] Lease Arrangement [Domain] Lease Arrangement [Domain] [Domain] for Lease Arrangement [Axis] Number of outstanding research and development targets Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets 12 Months or Greater, Fair Value Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer Total liabilities and stockholders’ equity Liabilities and Equity Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Amounts accrued for property and equipment Capital Expenditures Incurred but Not yet Paid Entity Address, City or Town Entity Address, City or Town Accrued compensation and related expenses Employee-related Liabilities, Current Subsequent Events Subsequent Events [Text Block] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Operating lease cost Operating Lease, Cost General and administrative General and Administrative Expense Financial Instrument [Axis] Financial Instrument [Axis] Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Deferred Revenue Arrangement [Line Items] Deferred Revenue Arrangement [Line Items] Dilutive securities excluded from computation of net loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Filing of the first MAA - first indication Filing of MMA - First Indication [Member] Filing of MMA - First Indication Loss on disposal of tenant improvements and certain equipment Gain (Loss) on Disposition of Property Plant Equipment Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Employee stock Employee Stock [Member] Equity Component [Domain] Equity Component [Domain] 2017 Employee Stock Purchase Plan Employee Stock Purchase Plan, 2017 [Member] Employee Stock Purchase Plan, 2017 [Member] Income Statement Location [Axis] Income Statement Location [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Income Statement Location [Domain] Income Statement Location [Domain] Stock-based compensation APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition Anti-PD-1 (CC-90006) AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member] AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member] Anti-LAG-3 (GSK40974386) AnaptysBio Generated Anti-LAG-3 (GSK40974386) [Member] AnaptysBio Generated Anti-LAG-3 (GSK40974386) 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Property and equipment, net Total property and equipment, net Property, Plant and Equipment, Net Available-for-sale Investments Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Revenue Revenue from Contract with Customer [Policy Text Block] Interest income Interest Income (Expense), Nonoperating, Net Equity Incentive Plans Share-based Payment Arrangement [Text Block] Net loss Net loss Net Income (Loss) Attributable to Parent Costs in Cash Flow Statement Lease, Cost [Table Text Block] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Other current liabilities Other Liabilities, Current 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three 2021 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Other long-term assets Other Assets, Noncurrent Plan Name [Axis] Plan Name [Axis] Comprehensive income (loss), net Other Comprehensive Income (Loss), Net of Tax Receivable from collaborative partners Receivables, Net, Current Total assets Assets Laboratory equipment Laboratory Equipment [Member] Laboratory Equipment [Member] Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Operating expenses: Operating Expenses [Abstract] Title of 12(b) Security Title of 12(b) Security Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Weighted average grant date fair value per share (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Subsequent Event Type [Axis] Subsequent Event Type [Axis] Unrealized (loss) income on available for sale securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Antidilutive Securities [Axis] Antidilutive Securities [Axis] Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] AnaptysBio-generated Zejula AnaptysBio-generated Zejula [Member] AnaptysBio-generated Zejula Shares Subject to Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Document Fiscal Period Focus Document Fiscal Period Focus Unrecognized compensation cost Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Not Yet Recognized, Stock Options Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Not Yet Recognized, Stock Options Depreciation and amortization Depreciation, Depletion and Amortization Lease term Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Certificates of deposit Certificates of Deposit [Member] Product and Service [Axis] Product and Service [Axis] SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Supplemental Cash Flow Information [Abstract] Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Entity Filer Category Entity Filer Category Fair Value Debt Securities, Available-for-sale, Unrealized Loss Position Common Stock Common Stock [Member] Product and Service [Domain] Product and Service [Domain] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Schedule of Milestones Achieved Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Phase 1 clinical trial initiation Phase 1 Clinical Trial Initiation [Member] Phase 1 Clinical Trial Initiation [Member] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Quoted Market Prices for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Upfront license fee received Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received Property and Equipment, net Property, Plant and Equipment [Table Text Block] Milestone payments, contingent upon certain U.S. and European regulatory submissions and approvals (up to) Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Less than 12 Months, Fair Value Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months US Treasury Securities US Treasury Securities [Member] Leasehold improvements Leasehold Improvements [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Less than 12 Months, Gross Unrealized Losses Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Money market funds Money Market Funds [Member] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Class of Stock [Line Items] Class of Stock [Line Items] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Shares issued under employee stock plans (in shares) Exercises (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Net increase (decrease) in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Total other income, net Nonoperating Income (Expense) Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Schedule of Future Minimum Annual Obligations Lessee, Operating Lease, Liability, Maturity [Table Text Block] Options to purchase common stock Share-based Payment Arrangement, Option [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Research and development Research and Development Expense Subsequent Events [Abstract] Subsequent Events [Abstract] Subsequent event Subsequent Event [Member] Milestone payment earned Revenue Recognized, Milestone Method, Milestone Payment Earned Revenue Recognized, Milestone Method, Milestone Payment Earned Stock options outstanding, beginning balance (in dollars per share) Stock options outstanding, ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Common stock, shares authorized (in shares) Common Stock, Shares Authorized Plan Name [Domain] Plan Name [Domain] Property and equipment, gross Property, Plant and Equipment, Gross Proceeds from issuance of common stock, upon the exercise of stock options Proceeds from Stock Options Exercised Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Entity Addresses [Table] Entity Addresses [Table] Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Anti-TIM-3 (GSK4069889A/Cobolimab) AnaptysBio Generated Anti-TIM-3 (GSK4069889A/Cobolimab) [Member] AnaptysBio Generated Anti-TIM-3 (GSK4069889A/Cobolimab) Additional paid in capital Additional Paid in Capital Filing of the first BLA - first indication Filing of BLA - First Indication [Member] Filing of BLA - First Indication Milestones achieved, amount Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount Income Statement [Abstract] Income Statement [Abstract] Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Title of Individual [Domain] Title of Individual [Domain] Accrued expenses Total accrued expenses Accrued Liabilities, Current Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Local Phone Number Local Phone Number Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Use of Estimates Use of Estimates, Policy [Policy Text Block] Current assets: Assets, Current [Abstract] Address Type [Domain] Address Type [Domain] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two 10770 Wateridge Circle, San Diego, California 92121 10770 Wateridge Circle, San Diego, California 92121 [Member] 10770 Wateridge Circle, San Diego, California 92121 Entity Emerging Growth Company Entity Emerging Growth Company Shares issued under employee stock plans Stock Issued During Period, Value, Stock Options Exercised Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Agreement term following first commercial sale or expiration of the last to expire patent (in years) Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Number of milestones achieved during period Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period Lease Arrangement [Axis] Lease Arrangement [Axis] Lease Arrangement [Axis] Award Type [Axis] Award Type [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment City Area Code City Area Code Maximum Maximum [Member] Phase 2 clinical trial initiation Phase 2 Clinical Trial Initiation [Member] Phase 2 Clinical Trial Initiation [Member] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Revenue recognition multiple deliverable arrangements upfront fee receivable Revenue Recognition Multiple Deliverable Arrangements Upfront Fees Revenue Recognition Multiple Deliverable Arrangements Upfront Fees Document Period End Date Document Period End Date Accumulated Deficit Retained Earnings [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Allowance for credit losses Debt Securities, Available-for-sale, Allowance for Credit Loss Gross Unrealized Losses Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss Common stock, shares reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Director Stock options Director [Member] Weighted average remaining contractual term, options outstanding (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Weighted average period remaining for amortization of unrecognized compensation cost (in years) Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not Yet Recognized, Period For Recognition Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not Yet Recognized, Period For Recognition Security deposit Security Deposit Award Type [Domain] Award Type [Domain] EMA conditional marketing authorization European Medicines Agency, Conditional Marketing Authorization [Member] European Medicines Agency, Conditional Marketing Authorization Trading Symbol Trading Symbol Stock options exercisable, ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Summary of Non-cash Stock-based Compensation Expense Share-based Payment Arrangement, Cost by Plan [Table Text Block] Office furniture and equipment Office Equipment [Member] Cover [Abstract] Cover [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Current liabilities: Liabilities, Current [Abstract] Entity Shell Company Entity Shell Company Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Lease renewal term Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term Schedule of Unrealized Loss and Fair Values in a Loss Position Schedule of Unrealized Loss on Investments [Table Text Block] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Initiated in vivo toxicology studies using good laboratory practices (GLPs) In Vivo Toxicology Studies [Member] In Vivo Toxicology Studies [Member]